Clinical trials: Alcoholic Liver Disease
Non-Alcoholic Fatty Liver Disease
Effect of Dapagliflozin on Metabolic Parameters in Patients With Non-Alcoholic Fatty Liver Disease
This study was designed to assess the effect of dapagliflozin on body weight, blood sugar, liver enzymes, and blood fats in adults with non-alcoholic fatty liver disease (NAFLD), a condition involving excess fat accumulation in…
- Trial name
- NCT07881796
- Testing
- Dapagliflozin (10mg Tab)
- Where
- Pakistan
- Volunteers
- 146 people
- Sponsor
- Shalamar Hospital
Non-Alcoholic Fatty Liver Disease
Clinical Trial Assessing Godex Carnitine Orotate Complex in Nonalcoholic Fatty Liver Disease Patients for Efficacy
the purpose of this clinical trial is to assess the efficacy and safety of Orotic Acid Carnitine Complex Capsules (Godex®) in comparison to a placebo control group in patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
- Trial name
- NCT06152991
- Testing
- GODEX
- Where
- South Korea
- Volunteers
- 196 people
- Sponsor
- Yoon Jun Kim
Coronary Disease, Coronary Arteriosclerosis
Effects of a Healthy Nordic Diet on Atherosclerosis in Patients with Coronary Heart Disease
Diet can play a key role in atherosclerosis and coronary heart disease (CHD), but little interventional data exists, and the mediators of possible anti-atherosclerotic effects of diet are unclear.
- Conditions
- Coronary Disease, Coronary Arteriosclerosis, Myocardial Infarction, Chronic Coronary Syndrome
- Trial name
- NORDHEART (NCT06701968)
- Testing
- Healthy Nordic Diet, Usual Care
- Where
- Sweden
- Volunteers
- 150 people
- Sponsor
- Uppsala University
Non-alcoholic Fatty Liver Disease (NAFLD), Dyslipidaemia
Study of ECC4703 With Sulfasalazine and Pitavastatin
Non-alcoholic fatty liver disease is a chronic, serious, life-threatening, inflammatory liver disease characterized by increased liver fat content, inflammation, and progressive fibrosis.
- Trial name
- NCT07726368
- Testing
- ECC4703, Sulfasalazine, Pitavastatin
- Where
- Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Eccogene
Visceral Obesity, Non-alcoholic Fatty Liver
Effect of Multi-ingredient on Visceral Adiposity & Non-alcoholic Fatty Liver Disease in Postmenopausal Women With Abdominal Obesity
This study aims to evaluate the effect of daily intake of a specific combination of different natural histidine-related amino acids in combination with dietary recommendations, in the reduction of visceral fat, as well as their…
- Conditions
- Visceral Obesity, Non-alcoholic Fatty Liver, Postmenopausal
- Trial name
- FATHIS+ (NCT06377631)
- Testing
- Multi-ingredient of L-histidine, L-serine, L-carnosine and N-Acetylcysteine
- Where
- 2 sites in Spain
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundació Eurecat
Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)
Long-term Follow-up to Determine Outcome in Liver Disease (LOVE Study)
The rational to conduct the LOVE study builds on the lack of available data on outcomes in steatotic liver disease in well characterized patients over a time frame of several years.
- Conditions
- Steatotic Liver Disease, MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis), Steatotic Liver Disease of Mixed Origin (MetALD), ALD - Alcoholic Liver Disease
- Trial name
- LOVE (NCT06907563)
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 30,000 people
- Sponsor
- Universität des Saarlandes
Non-alcoholic Steatohepatitis
A Research Study Looking at How the Medicine NNC0194-0499 Behaves in Japanese and Non-Asian Men
This study looks at how a new medicine called NNC0194-0499 works in the body of Japanese men and non-Asian men. Japanese participants will either get NNC0194-0499 or placebo - which treatment participants get is decided by…
- Trial name
- NCT04722653
- Testing
- NNC0194-0499
- Where
- Japan
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Fatty Liver, Nonalcoholic
Efficacy and Safety of Fermented Ginseng Powder on Liver Function
This study was conducted to investigate the effects of daily supplementation of fermented ginseng powder on improvement of Liver function.
- Trial name
- NCT03260543
- Testing
- fermented ginseng powder
- Where
- South Korea
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Chonbuk National University Hospital
Non Alcoholic Fatty Liver Disease, Type2 Diabetes Mellitus
Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
This D-LIFT (Effect of dulaglutide on Liver Fat) trial is an investigator initiated, prospective, open label, randomized clinical study to examine the effect of dulaglutide 0.75 mg subcutaneously weekly for 4 weeks, followed by…
- Trial name
- D-LIFT (NCT03590626)
- Testing
- Dulaglutide
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Medanta, The Medicity, India
Fatty Liver Disease
A Clinical Study of Ultrasound-derived Fat Fraction to Assess Metabolic Dysfunction-Associated Steatotic Liver Disease
Aims: To evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) in assessing the degree of hepatic steatosis in an obese population, with liver biopsy as reference standard.
- Trial name
- NCT06487325
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Ma Zhe
Alcoholic Hepatitis
Prothrombin Time Predicts Steroid Response in Severe Alcoholic Hepatitis.
Alcoholic hepatitis (AH) is the most severe form of acute alcohol-related liver disease. Maddrey's discriminant function (mDF) >32 defines the severe form of AH, which is associated with a high mortality.
- Trial name
- AH2023 (NCT05883891)
- Testing
- prothrombin time
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis
De Novo Lipogenesis in Severity of NAFLD
NAFLD is the most prevalent liver disease in the U.S., and there is a serious need to understand its progression to the advanced state, nonalcoholic steatohepatitis (NASH).
- Conditions
- Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, Bariatric Surgery Candidate, Obesity, Morbid
- Trial name
- NCT03683589
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Missouri-Columbia
Fatty Liver, Obesity
Study of the Efficacy and Safety of Nicotinamide in Patients With Liver Fibrosis (NICOFIB)
The objective of this clinical trial, a pilot study, is to assess the impact of nicotinamide (NAM) on individuals with hepatic fibrosis.
- Conditions
- Fatty Liver, Obesity, Hepatic Fibrosis, NAFLD
- Trial name
- NICOFIB (NCT06599918)
- Testing
- Nicotinamide
- Where
- Spain
- Volunteers
- 30 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
NASH - Nonalcoholic Steatohepatitis, NAS
Hepatic Energy Fluxes in NASH and NAS Patients
Diseases along the nonalcoholic fatty liver disease spectrum, which are tightly coupled to the obesity epidemic, are soon to become the commonest indication for liver transplantation in the United States.
- Conditions
- NASH - Nonalcoholic Steatohepatitis, NAS, Overweight or Obesity, Weight Loss
- Trial name
- NCT03997422
- Testing
- Vertical Sleeve Gastrectomy (VSG)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Minnesota
NASH - Nonalcoholic Steatohepatitis
A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis
The primary objective of the study is to compare the changes in serum ALT level among patients with non-alcoholic steatohepatitis (NASH) following 3-month treatment of 800 mg SNP-610 or the placebo.
- Trial name
- NCT03468556
- Testing
- SNP-610
- Volunteers
- 80 people
- Sponsor
- Sinew Pharma Inc.
Nonalcoholic Fatty Liver Disease
Gastric Bypass Stent Small-Sample-Size Study For Nonalcoholic Fatty Liver Disease
Evaluate the preliminary effectiveness and safety of the Gastric Bypass Stent System in treating nonalcoholic fatty liver disease.
- Trial name
- NCT05495139
- Testing
- Gastric Bypass Stent System in Treatment of Patients with Nonalcoholic Fatty Liver Disease
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hangzhou Tangji Medical Technology Co., Ltd.
Post Liver Transplantation Weight Gain, Post Liver Transplantation Obesity
Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity
This study is to assess value of providing classes about dietary and life style modifications to decrease or prevent weight gain, less occurrence or better control of weight gain associated disorders such as high blood sugar…
- Conditions
- Post Liver Transplantation Weight Gain, Post Liver Transplantation Obesity, Nonalcoholic Steatohepatitis
- Trial name
- NCT00878592
- Testing
- Dietary and life style modification
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Pittsburgh
NAFLD
Rutin and Vitamin C in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
evaluate the combined effects of Rutin and Vitamin C versus Vitamin C alone on selected oxidative stress markers, inflammation, hepatic steatosis regression, and associated metabolic parameters in patients with MASLD
- Trial name
- NCT07310407
- Testing
- Rutin + Vitamin C, Vitamin C 500mg, Lifestyle Intervention
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Ain Shams University
Fatty Liver
Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease
Moderate exercise with a low fat and/or a moderate fat with low processed carbohydrate diet will have a greater effect on slowing disease progression and reversing hepatic steatosis and/or necro-inflammation in the liver of adult…
- Trial name
- NAFLD (NCT00815009)
- Testing
- Mod Fat/Low Processed Carb Diet and Moderate Exercise, Low Fat Diet and Moderate Exercise, Moderate Exercise Only
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- San Antonio Military Medical Center
Obesity
Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.
It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients within this group have a more serious liver…
- Trial name
- NCT00280527
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Northwestern University